Edmund Liang Chai Ong, Speaker at Infectious Diseases Conferences
Physician

Edmund Liang Chai Ong

Newcastle University Medicine Malaysia, Malaysia

Abstract:

Background: Tuberculosis (TB) remains the leading cause of death from a single infectious agent and the foremost killer of people living with HIV. Despite decades of progress, HIV-associated TB continues to exact a disproportionate toll, particularly in low- and middle-income countries. Emerging funding constraints and widening health inequities threaten to reverse gains achieved through integrated HIV and TB programs.

Current Burden: According to the WHO Global Tuberculosis Report 2025, an estimated 10.8 million people developed TB in 2024, resulting in 1.23 million deaths, including approximately 150,000 deaths among people living with HIV. Globally, nearly 41 million people were living with HIV in 2024, with 1.3 million new infections and 630,000 AIDS-related deaths. TB remains the leading opportunistic infection and cause of mortality among people living with HIV despite the availability of effective antiretroviral therapy (ART), tuberculosis preventive treatment (TPT), and rapid molecular diagnostics.

Challenges and Opportunities: Although ART scale-up and integrated HIV-TB services have significantly reduced mortality over the past decade, progress has slowed. Disruptions in prevention and treatment programs, declining international funding, antimicrobial resistance, and persistent gaps in early diagnosis threaten global targets. Modeling by UNAIDS suggests that sustained reductions in HIV financing could lead to millions of additional HIV infections and AIDS-related deaths by 2029. Conversely, innovations including shorter TB preventive regimens, next-generation molecular diagnostics, long-acting antiretrovirals, and differentiated service delivery offer unprecedented opportunities to accelerate progress.

Conclusion: HIV and TB remain a deadly syndemic requiring coordinated, people-centered, and adequately funded responses. Achieving the Sustainable Development Goals and ending both epidemics as public health threats will depend on strengthened integration of HIV and TB services, expanded access to prevention and treatment, investment in innovation, and renewed global solidarity. Failure to act decisively risks reversing decades of progress and perpetuating one of the most devastating infectious disease partnerships of our time.

Keywords: HIV; tuberculosis; HIV-associated tuberculosis; syndemic; antiretroviral therapy; tuberculosis preventive treatment; global health.

Biography:

Professor Edmund L. C. Ong is an Infectious Diseases physician and academic who graduated from the University of Newcastle Medical School, UK, and undertook specialist training in Infectious Diseases, Tropical Medicine and General Internal Medicine in the United Kingdom. He is currently a Visiting Professor in Practice at Newcastle University Medicine Malaysia.

His clinical and research interests encompass opportunistic infections, HIV, tuberculosis, dengue and other tropical infections, the evaluation of anti-infective agents, clinical epidemiology, and innovation in healthcare quality improvement and clinical audit.

Professor Ong has served as Principal Investigator and collaborator in numerous international research projects involving HIV, tuberculosis and dengue, with research and clinical collaborations spanning Nigeria, South Africa, Myanmar and Malaysia. He has contributed to several textbooks on infectious diseases and has authored or co-authored more than 200 publications in peer-reviewed scientific journals.

He serves on the editorial boards of several scientific journals, including Tropical Medicine and Infectious Disease and Advances in Medicine and Health Sciences. He is also an experienced examiner for undergraduate and postgraduate medical examinations, including MRCP(UK), the Diploma in HIV Medicine and Master of Medicine (MMed) programmes.

His professional leadership includes serving as International Global Advisor (Malaysia) to the Royal College of Physicians, London, and as former Chair of the British HIV Association (BHIVA) Audit and Standards of Care Committee. He remains actively involved in international medical education, research collaboration and the advancement of clinical standards in infectious diseases.

WhatsApp
Top